JP2016506908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506908A5 JP2016506908A5 JP2015552819A JP2015552819A JP2016506908A5 JP 2016506908 A5 JP2016506908 A5 JP 2016506908A5 JP 2015552819 A JP2015552819 A JP 2015552819A JP 2015552819 A JP2015552819 A JP 2015552819A JP 2016506908 A5 JP2016506908 A5 JP 2016506908A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- composition according
- albumin
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710113436 GTPase KRas Proteins 0.000 claims description 20
- 230000035772 mutation Effects 0.000 claims description 15
- 102000009027 Albumins Human genes 0.000 claims description 12
- 108010088751 Albumins Proteins 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 229940123237 Taxane Drugs 0.000 claims description 10
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 10
- 102200007373 rs17851045 Human genes 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 102200006657 rs104894228 Human genes 0.000 claims description 4
- 102200006532 rs112445441 Human genes 0.000 claims description 4
- 102200006520 rs121913240 Human genes 0.000 claims description 4
- 102200006531 rs121913529 Human genes 0.000 claims description 4
- 102200006537 rs121913529 Human genes 0.000 claims description 4
- 102200006539 rs121913529 Human genes 0.000 claims description 4
- 102200006538 rs121913530 Human genes 0.000 claims description 4
- 102200006540 rs121913530 Human genes 0.000 claims description 4
- 102200006541 rs121913530 Human genes 0.000 claims description 4
- 102220197834 rs121913535 Human genes 0.000 claims description 4
- 102200006648 rs28933406 Human genes 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102220014333 rs112445441 Human genes 0.000 claims description 3
- 102200006533 rs121913535 Human genes 0.000 claims description 3
- 102220640055 Alpha-mannosidase 2_G12L_mutation Human genes 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102220530637 Putative apolipoprotein(a)-like protein 2_G12F_mutation Human genes 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 102200006562 rs104894231 Human genes 0.000 claims description 2
- 102220197831 rs121913527 Human genes 0.000 claims description 2
- 102200006564 rs121917759 Human genes 0.000 claims description 2
- 102220334606 rs1348427922 Human genes 0.000 claims description 2
- 102220293980 rs143960528 Human genes 0.000 claims description 2
- 102200007376 rs770248150 Human genes 0.000 claims description 2
- 230000000869 mutational effect Effects 0.000 claims 1
- 102220197833 rs112445441 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 102200006525 rs121913240 Human genes 0.000 description 3
- 102220197780 rs121434596 Human genes 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361848793P | 2013-01-11 | 2013-01-11 | |
| US61/848,793 | 2013-01-11 | ||
| US201361752417P | 2013-01-14 | 2013-01-14 | |
| US61/752,417 | 2013-01-14 | ||
| US13/794,712 | 2013-03-11 | ||
| US13/794,712 US20140199405A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on mutation status of k-ras |
| PCT/US2014/011097 WO2014110408A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506908A JP2016506908A (ja) | 2016-03-07 |
| JP2016506908A5 true JP2016506908A5 (enExample) | 2017-02-16 |
Family
ID=51165319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552819A Pending JP2016506908A (ja) | 2013-01-11 | 2014-01-10 | Ｋ−ｒａｓの変異状態に基づくがんの処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140199405A1 (enExample) |
| EP (1) | EP2943184A4 (enExample) |
| JP (1) | JP2016506908A (enExample) |
| KR (1) | KR20150103746A (enExample) |
| AU (1) | AU2014205254A1 (enExample) |
| BR (1) | BR112015016466A2 (enExample) |
| CA (1) | CA2897581A1 (enExample) |
| HK (1) | HK1217292A1 (enExample) |
| IL (1) | IL239740A0 (enExample) |
| MX (1) | MX2015008889A (enExample) |
| WO (1) | WO2014110408A1 (enExample) |
| ZA (1) | ZA201504878B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| EP2949763A3 (en) | 2006-08-11 | 2016-03-09 | Johns Hopkins University | Consensus coding sequences of human breast cancers |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| CN106414493A (zh) | 2014-05-06 | 2017-02-15 | 塔格瓦克斯公司 | 包含突变的ras肽和化疗剂的肽疫苗 |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| WO2018067943A1 (en) * | 2016-10-07 | 2018-04-12 | Abraxis Bioscience, Llc | Methods of treating biliary tract cancer |
| EP3444272A1 (en) * | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| EP4146346A4 (en) * | 2020-05-08 | 2025-05-14 | Cardiff Oncology, Inc. | Methods of monitoring kras mutations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG166775A1 (en) * | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2007001868A1 (en) * | 2005-06-28 | 2007-01-04 | Genentech, Inc. | Egfr and kras mutations |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| HRP20140360T4 (hr) * | 2007-03-13 | 2022-06-10 | Amgen, Inc. | K-ras mutacije i terapija anti-egfr antitijelom |
| WO2011116181A1 (en) * | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| SG178873A1 (en) * | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| KR101894689B1 (ko) * | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| AU2011255438A1 (en) * | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US9945862B2 (en) * | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013134786A2 (en) * | 2012-03-09 | 2013-09-12 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
-
2013
- 2013-03-11 US US13/794,712 patent/US20140199405A1/en not_active Abandoned
-
2014
- 2014-01-10 JP JP2015552819A patent/JP2016506908A/ja active Pending
- 2014-01-10 KR KR1020157021321A patent/KR20150103746A/ko not_active Withdrawn
- 2014-01-10 BR BR112015016466A patent/BR112015016466A2/pt not_active Application Discontinuation
- 2014-01-10 CA CA2897581A patent/CA2897581A1/en not_active Abandoned
- 2014-01-10 HK HK16105270.2A patent/HK1217292A1/zh unknown
- 2014-01-10 EP EP14738060.4A patent/EP2943184A4/en not_active Withdrawn
- 2014-01-10 AU AU2014205254A patent/AU2014205254A1/en not_active Abandoned
- 2014-01-10 MX MX2015008889A patent/MX2015008889A/es unknown
- 2014-01-10 WO PCT/US2014/011097 patent/WO2014110408A1/en not_active Ceased
-
2015
- 2015-07-01 IL IL239740A patent/IL239740A0/en unknown
- 2015-07-07 ZA ZA2015/04878A patent/ZA201504878B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506908A5 (enExample) | ||
| JP2016513075A5 (enExample) | ||
| JP2016512506A5 (enExample) | ||
| JP2016505018A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| JP2013523656A5 (enExample) | ||
| JP2013533232A5 (enExample) | ||
| BR112012024442A2 (pt) | métodos de tratamento de câncer | |
| JP2015536950A5 (enExample) | ||
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| NZ708506A (en) | Methods of treating bladder cancer | |
| JP2017008088A5 (enExample) | ||
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| JP2017517520A5 (enExample) | ||
| JP2019526543A5 (enExample) | ||
| JP2019532051A5 (enExample) | ||
| SA515361055B1 (ar) | نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون | |
| MX2012011155A (es) | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. | |
| NZ573555A (en) | Nanoparticulate posaconazole formulations | |
| JP2016513657A5 (enExample) | ||
| JP2018535996A5 (enExample) | ||
| Wang et al. | A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002) | |
| BR112015032758A2 (pt) | nanopartículas poliméricas de docetaxel para o tratamento de câncer | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| WO2015031598A3 (en) | Therapeutic dnp derivatives and methods using same |